MGC Pharmaceuticals
About MGC Pharmaceuticals
MGC Pharmaceuticals is a European pharmaceutical company listed on the London Stock Exchange, specializing in the production and development of cannabinoid-based medicines. The company operates manufacturing facilities in Malta and Slovenia, and is developing its flagship product CannEpil for drug-resistant epilepsy. MGC Pharma pursues a pharmaceutical-grade approach with clinical trials and regulatory approvals.
Key Facts
- 1Listed on the London Stock Exchange under ticker MXC
- 2Developing CannEpil for drug-resistant epilepsy through clinical trials
- 3Operates EU-GMP manufacturing facilities in Malta and Slovenia
- 4Originally founded in Australia before relisting on the LSE
Frequently Asked Questions
What is CannEpil?
CannEpil is MGC Pharmaceuticals' lead product candidate, a cannabinoid-based medicine being developed for drug-resistant epilepsy. It is undergoing clinical trials with the goal of obtaining pharmaceutical regulatory approval.
Where does MGC Pharmaceuticals manufacture its products?
MGC Pharma operates EU-GMP-certified manufacturing facilities in Malta (through its AusGreenPharma joint venture) and in Slovenia, providing pharmaceutical-grade production capabilities.
More Cannabis Companies in London
Cannabis Laws
Products
- CannEpil (epilepsy medication in development)
- CogniCann (dementia research product)
- EU-GMP phytocannabinoid medicines
Specialties
Company Details
- Type
- Medical & Pharma
- Location
- London, United Kingdom
- Founded
- 2014
- Publicly Traded
- Yes
- Ticker
- LSE:MXC